Danaher Corporation $DHR Shares Acquired by Concurrent Investment Advisors LLC

Key Points

• Concurrent Investment Advisors LLC increased its holdings in Danaher Corporation by 14% in Q2, now owning 11,459 shares worth approximately $2.26 million.
• Institutional investors and hedge funds collectively own 79.05% of Danaher's stock, highlighting significant interest in the company from large financial entities.
• Danaher recently declared a quarterly dividend of $0.32 per share, representing an annual yield of 0.6% and a payout ratio of 27.23%.

Concurrent Investment Advisors LLC boosted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 14.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,459 shares of the conglomerate's stock after acquiring an additional 1,411 shares during the period. Concurrent Investment Advisors LLC's holdings in Danaher were worth $2,264,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Invesco Ltd. raised its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after purchasing an additional 163,332 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Up 0.5%

DHR stock opened at $206.19 on Wednesday. The company has a market cap of $147.64 billion, a price-to-earnings ratio of 43.87, a PEG ratio of 2.92 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $200.96 and a 200-day simple moving average of $197.13. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher's dividend payout ratio is presently 27.23%.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.20% of the stock is owned by insiders.

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. Bank of America cut their price objective on shares of Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a research report on Monday, September 22nd. Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Finally, Redburn Partners set a $220.00 target price on Danaher in a research note on Wednesday, October 8th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $244.60.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.